企業(yè)檔案
- 會(huì)員類型：免費(fèi)會(huì)員
- 工商認(rèn)證： 【已認(rèn)證】
- 最后認(rèn)證時(shí)間：
- 法人：
- 注冊(cè)號(hào)：
- 企業(yè)類型：經(jīng)銷商
- 注冊(cè)資金：人民幣100萬(wàn)
Unique
美國(guó) BioSpec
美國(guó)Millpore
瑞士Keller
德國(guó)Chemvck
德國(guó)Wiggens
法國(guó)Interscience
美國(guó)TYLER
美國(guó)BioProducts MD
法國(guó)Hyphen Biomed
德國(guó)Brand
美國(guó)ABI
美國(guó)Nalgene
加拿大Labplas
德國(guó)Greiner
美國(guó)wheaton
美國(guó)kimble
美國(guó)Corning
Thermo
Bioproducts MD
GILSON
BD
臺(tái)灣 ABNOVA
瑞士SOCOREX
聯(lián)系我們
聯(lián)系人：錢海婷
熱門標(biāo)簽
友情鏈接
- 太倉(cāng)柴油批發(fā)
- 保健按摩服務(wù)：
- 冷熱沖擊試驗(yàn)箱
- 標(biāo)準(zhǔn)品
- 公司成立以來(lái)一直專注于世界品牌望遠(yuǎn)鏡
- 伺服電機(jī)驅(qū)動(dòng)器
- 粉末真密度檢測(cè)儀
- 開(kāi)展各類檢測(cè)業(yè)務(wù)各類檢測(cè)設(shè)備的
- 技術(shù)轉(zhuǎn)讓
- 通用分析儀器
- 深圳市賽德力檢測(cè)設(shè)備有限公司
- 無(wú)線氣象站
- GC-7900系列
- 技術(shù)轉(zhuǎn)讓
- PLC可編程控制器
- ELISA免費(fèi)代測(cè)
- 水泥試驗(yàn)儀器
- 北京小池文化傳媒有限公司
- 絕緣耐壓
- 調(diào)節(jié)閥
公司動(dòng)態(tài)
Quidel Products Price List U.S.
點(diǎn)擊次數(shù)：511 發(fā)布時(shí)間：2017/7/17
Quidel Corporation （Nasdaq: QDEL） is a California-based leading diagnostic healthcare manufacturer serving to enhance the health ａnd well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes ａnd provide economic benefits to the healthcare system.
Quidel commenced operations in 1979 ａnd launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development ａnd acquisition with a focus on increasing its research ａnd development efforts to accelerate the rate of new product introductions. Our core competencies ａnd capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization ａnd development, ａnd molecular assay development. Our current products fall generally into these categories: （1） lateral flow, where we are market leaders in infectious disease ａnd reproductive health; （2） direct fluorescent antibodies （DFA）, with expertise in infectious disease ａnd virology; （3） micro-titer production, with a focus on bone ａnd complement pathway markets; （4） fluorescent immunoassay products （Sofia）; ａnd （5） molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular ａnd Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in San Diego, California, at our research ａnd manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow ａnd direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
Quidel commenced operations in 1979 ａnd launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development ａnd acquisition with a focus on increasing its research ａnd development efforts to accelerate the rate of new product introductions. Our core competencies ａnd capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization ａnd development, ａnd molecular assay development. Our current products fall generally into these categories: （1） lateral flow, where we are market leaders in infectious disease ａnd reproductive health; （2） direct fluorescent antibodies （DFA）, with expertise in infectious disease ａnd virology; （3） micro-titer production, with a focus on bone ａnd complement pathway markets; （4） fluorescent immunoassay products （Sofia）; ａnd （5） molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular ａnd Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in San Diego, California, at our research ａnd manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow ａnd direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
